Further Expansion in Spain for EarlyCDT Lung

RNS Number : 4570F

Oncimmune Holdings PLC

15 July 2019

 

15 July 2019

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Further Expansion in Spain for EarlyCDT^® Lung as a Screening Test

Oncimmune Holdings plc (AIM: ONC.L), a leading global immunodiagnostics group, today announces Sabartech S.L. ("Sabartech"), its existing distributor in Spain and Portugal, has successfully signed an agreement with Vithas Group, the Spanish private healthcare group, to sell EarlyCDT^® Lung as a screening test for early detection of lung cancer. In addition, Vithas Group's laboratory is also promoting the test across Spain to further increase awareness of EarlyCDT Lung.

This is the latest in a series of commercial agreements to increase the reach of EarlyCDT Lung in large European and North American healthcare markets and validate the product's increasing acceptance within major healthcare systems.

Vithas Group operates 48 hospitals and medical centres across Spain and has been growing strongly through the opening of new facilities, such as its Granada hospital in 2016, and strategic acquisitions such as Nisa Hospitals and Rincon Clinics in 2017. More than 5.2 million patients attend the Vithas Group medical centres, positioning the Vithas Group as the second-largest private medical group in Spain. In March 2019 we also announced a commercial agreement with Quirónsalud Group, Spain's largest private hospital network with 46 hospitals, 56 outpatient centres and some 300 occupational risk centres.

Every year in Spain approximately 27,000 new cases of lung cancer are diagnosed and 23,000 deaths occur from the disease. Lung cancer is the largest cause of cancer-related deaths in Spain.^[1]

Dr Adam M Hill, CEO of Oncimmune commented: "Today's announcement further demonstrates the success of our partnership with Sabartech for the distribution of EarlyCDT Lung across the Iberian Peninsula. The news highlights the growing momentum behind our business and further validates our strategy of creating value through partnering to unlock the potential of the EarlyCDT portfolio."

-Ends-

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Mike Seabrook

[phone]

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

[phone]

Media enquiries:

FTI Consulting

Brett Pollard, Andrew Ward, Michael Trace, Alexander Davis

[e-mail]

[phone]

About Oncimmune

Beating cancer, one test at a time

Oncimmune is a leader in the development, manufacture and commercialisation of cancer specific immunodiagnostics for the screening, detection and care of cancer. Oncimmune also develops precision medicine and patient stratification tools for leading pharmaceutical multinationals in both autoimmune disease and immuno-oncology. Oncimmune is working to change how cancer is diagnosed and treated. Its patented technology detects evidence of the body's natural response to cancer, enabling detection four years or more before standard clinical diagnosis. Oncimmune's tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. Oncimmune partners with leading developers and distributors to make our technology available globally.

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT Lung and EarlyCDT^® Liver. To date, over 155,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled study for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland which demonstrated EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a CLIA lab in Kansas, US as well as an office in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

What is EarlyCDT Lung?

A blood test using a panel of seven immunogenic proteins for the testing of tumour-related antibodies specific to lung cancer.

For more information, visit www.oncimmune.com.

 

---

[1] GLOBOCAN 2018 (WHO)

 

END

 

 

NRALFFVLDSISLIA